Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -1.97% 7.45 7.20 7.70 7.60 7.45 7.60 154,860 12:32:54
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 20

Evgen Pharma Share Discussion Threads

Showing 8076 to 8098 of 8400 messages
Chat Pages: Latest  324  323  322  321  320  319  318  317  316  315  314  313  Older
DateSubjectAuthorDiscuss
06/4/2021
21:16
Anyways, a 1.5m sell and a 2m trade after hours, anyones guess, 15m plus traded volume today and the share price closed 10% up, a corner turned imho and more of the same in anticipation of news, especially from Prof Chalmes Covid/Ards efficacy assessment, which will be a defining moment and maybe one that will propel Evgen into the global spotlight if data correlates to John Hopkins research. Gla :-)
moneymunch
06/4/2021
18:46
A sleeper in the Evgen portfolio is its deal with entrepreneur Jim Mellon’s Juvenescence, which has licensed the non-pharmaceutical/nutraceutical rights to the Sulforadex platform. The tie-up is worth around US$10.5mln in milestone payments and future royalties to Evgen. 06-Apr-2021 Juvenescence Appoints Dr. Grazia Piizzi as Chief Scientific Officer DOUGLAS, Isle of Man--(BUSINESS WIRE)--Juvenescence Limited (“Juvenescence”), a life sciences company focused on modifying aging and increasing human healthspan, announced today that Dr. Grazia Piizzi, PhD, has joined its Executive Management Team as Chief Scientific Officer. Juvenescence is based on a new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies. It is focused on increasing how long people live in health by preventing the diseases of aging in the first place. The Juvenescence team includes highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in the pharmaceutical and consumer health sectors. Dr. Piizzi has more than 15 years of experience in the global pharmaceutical and biotech industry. Most recently, she was the SVP of Small Molecules R&D and Head of Inflammation at a Flagship Pioneering startup, Cygnal Therapeutics, decoding the links between peripheral neurons and diseases (2019-2021). Previously, she held the position of Executive Director, Head of Molecular Invention, at Merck Cambridge (2017-2019) to build the new Exploratory Science Center (ESC) and establish a multidisciplinary team and platform to identify opportunities in infectious diseases, microbiome, and immune-cancer-microbiome interactions. Dr. Piizzi also spent 10 years at Novartis Cambridge and Basel leading global teams responsible from target ID to clinical candidate selection across multiple disease areas. Dr. Greg Bailey, CEO of Juvenescence, said: “Aging is an incredibly complex biological event where multiple pathologies compromise our ability to live healthy. For any company to address and modify how we age so that we can live healthier and longer, you need to be very inventive and innovative using combinations of therapies. Dr. Piizzi is an extraordinary fit because of her imagination and curiosity backed by rigorous scientific discipline. Juvenescence is very lucky to have someone with these qualities join us as our CSO. There are a number of areas that are going to be a focus for us going forward, and Dr. Piizzi’s background will accelerate and optimize these opportunities.” Dr. Piizzi said: “I’m focused on building the portfolio, bringing new skills, assets and technologies into this company. Science is changing how we look at aging and age-related diseases. I will work with a talented team to bring that science to real products and therapies that can transform lives.” hTtps://www.pharmiweb.com/press-release/2021-04-06/juvenescence-appoints-dr-grazia-piizzi-as-chief-scientific-officer
moneymunch
06/4/2021
17:14
The late reported 900k looks like a buy given its 14.58pm timing and the 1m plus trade is definitely a buy at 8.20p.....all bodes well...Gla ;-)
moneymunch
06/4/2021
17:07
Unmet Need COVID-19 is a worldwide problem, and infection rates continue to rise. Therefore, more therapies and prophylactics are urgently needed to suppress the rise of confirmed cases and reduce the mortality rate. Technology Overview Johns Hopkins researchers have invented a method to prevent and treat COVID-19. They proposed the use of sulforaphane (SF), a natural compound found in cruciferous vegetables (i.e. broccoli, kale), for COVID-19 prevention and treatment. Their in vitro experiments showed that SF inhibits SARS-CoV-2 replication, demonstrating the potential of SF to be a relatively cheap and widely available prophylactic and therapeutic against COVID-19. Stage of Development This technology is under pre-clinical development. publication: hTtps://www.biorxiv.org/content/10.1101/2021.03.25.437060v1 hTtp://jhu.technologypublisher.com/technology/43247
moneymunch
06/4/2021
14:58
>i like the story ( but more from the inflammation angle than the Covid angle..) Isn't the COVID/ARDS angle the inflammation angle mesequida (Nrf2 pathway)? Obviously there is now an anti-viral angle as well with the John Hopkins paper.
on target
06/4/2021
14:55
Ps the same self-proclaimed experts who said there would be no preliminary efficacy assessment on the Covid/ARDS patient trial, and were incensed at the reasonable speculation that there could be. Gl :-)
moneymunch
06/4/2021
14:44
Few and far between mesquida, and the final throes as the 125m placing shares settle in to firm hands, and as far as the Covid angle is concerned, you obviously must have missed the John Hopkins University research publication that pretty much validates Sulforaphane as an effective treatment for Covid-19, the majority of variants as well as ARDS etc, and perhaps you've been swayed by the opinions of the self-proclaimed experts who are on record that SFX-01 will never be approved and are also on record proclaiming that know more than Prof Chalmers does on the subject...ho ho ho ....not too much longer I reckon before we find out. Gl :-)
moneymunch
06/4/2021
14:36
Few and far between ? I have no wish to rain on your parade, moneymunch, but just a cursory glance at today's trades shows 3 sales of 1.1m , 1.5m (approx) and 400k ( approx) all of which were executed at a discount to the bid price at the time. And that is just after a cursory glance ! Dont get me wrong, i like the story ( but more from the inflammation angle than the Covid angle which you are ever eager to promote ), but until this Share Register tightens up it is difficult to see the share price making any meaningful progress.
mesquida
06/4/2021
14:16
Becoming few and far between mesquida, especially those prepared to sell 8p and under. There's a raft of material news expected this quarter that could drop at anytime, to drive the share price to new highs, including Prof Chalmers preliminary efficacy assessment of SFX-01 for Covid/ARDS, where positive data will be very well received. Gl :-)
moneymunch
06/4/2021
13:37
Yes, but clearly there are still sellers lurking in the undergrowth.
mesquida
06/4/2021
13:12
EVG was 14p not long ago.Crazy cheap entry and update due as well.imo
36jay
06/4/2021
12:34
Lol HH, in Huw we trust.:-)))
moneymunch
06/4/2021
12:26
5 baggers opportunity.Time to buy and hold.Next update will be massive.Dirt cheap entry.
36jay
06/4/2021
12:22
In MM we Trust!
hodhasharon
06/4/2021
11:42
christ, that didn’t take long 🤦🏼‍♂️🙄
bumpa33
06/4/2021
11:38
EVG EVG Mega deal inbound.Multi bagger opportunity.Dyor
36jay
06/4/2021
11:35
On the right side now, so its a wait and add as funds allow to become a multi bagger.
clocktower
06/4/2021
11:02
Hopefully so Rb, if it brings a few more onboard that can actually see the scale of the potential then all well and good. As for PR, I swear I’ve never met one who wasn’t cranially challenged to the ‘nth degree...
bumpa33
06/4/2021
10:57
Presumably today's volume is also a result of it being the first day of the new tax year, no more tax-loss selling, combined with investors buying to utilise thir new ISA allowance.
mesquida
06/4/2021
10:55
They don’t search the internet for sources of relevance or inspiration, more content to wait what is fed them by the hand that pays. Seems like your little gem of a find has got a few people thinking this morning.
riggerbeautz
06/4/2021
10:02
Thanks for the posts . Think I posted a few weeks ago and others maybe that Albena D-K is a special advisor to Evgen and is a prof at John Hopkins and the culman chempprotection offshoot . Looking forward to some movement again
peterm10
06/4/2021
09:42
I think that excellent find by bumpa33 could have brought in a few buyers. Really compelling read
muddy_40
06/4/2021
09:39
In a blink of an eye....;-)
moneymunch
Chat Pages: Latest  324  323  322  321  320  319  318  317  316  315  314  313  Older
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210515 18:32:34